Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC
2021-01-31
(Press-News.org) (Singapore--January 31, 2021 2:40 p.m. SPT 1:40 a.m. EST)--Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. The research was presented today at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer Singapore.
Lorlatinib, a third-generation ALK inhibitor, significantly improved progression-free survival compared to crizotinib in patients with previously untreated advanced ALK-positive NSCLC.
Dr. Julien Mazieres, Toulouse University Hospital, in Toulouse, France presented the detailed results of patient reported outcomes (PROs) from his same study.
CROWN enrolled 296 patients with ALK+ NSCLC and randomly assigned each to receive either lorlatinib or crizotinib. PROs were assessed using the EORTC QLQ-C30 and QLQ-LC13, and the EQ-5D-5L--assessments used to rate the health-related quality of life (QOL) of patients with cancer participating in international clinical trials. Each patient completed an assessment on the first day of each cycle (28 days) through end of treatment. Dr. Mazieres and her team measured time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough and compared these results between the two treatment arms.
Completion rates were 100% at baseline and remained high (? 96%) through cycle 18 in both treatment arms. There were no clinically meaningful or statistically significant differences between treatment arms in any functioning domain, with numerical improvements favoring lorlatinib in physical, role, emotional, and social functioning scales, and a numerical improvement favoring crizotinib for cognitive functioning.
According to Dr. Mazieres, there were statistically significant, but not clinically meaningful differences favoring lorlatinib in symptoms of fatigue, nausea and vomiting, insomnia, appetite loss, and constipation. For diarrhea there was both a clinically meaningful and statistically significant difference favoring lorlatinib.
Lung cancer symptoms improved from baseline in both treatment arms, with clinically meaningful improvements in cough as early as Cycle 2 and maintained through Cycle 18. TTD in the composite endpoint of lung cancer symptoms (cough, dyspnea, or pain in chest) was similar between treatment arms (HR 1.09; 95% CI: 0.82-1.44; 2-sided p = 0.5415). Median time to worsening of global QOL was 24.0 months for lorlatinib and 12.0 months for crizotinib (HR 0.92; 95% CI 0.65-1.29).
"Time to treatment deterioration for lung cancer symptoms was comparable between treatment arms. Improvements in lung cancer symptoms were seen early and clinically meaningful improvements in cough were detected in [patients who received] lorlatinib," Dr. Mazieres reported.
"Patient-reported outcomes in phase III CROWN support the improved PFS and are consistent with safety/tolerability of lorlatinib relative to crizotinib."
INFORMATION:
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes nearly 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC:
The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more nearly 7,500 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit wclc2020.iaslc.org.
ELSE PRESS RELEASES FROM THIS DATE:
2021-01-31
COVID-19 mortality racial disparities in the U.S. are associated with social factors like income, education and internet access, according to a Rutgers study.
The study, published in the Journal of Racial and Ethnic Health Disparities, highlights the need for public health policies that address structural racism.
The researchers investigated the association between COVID-19 cases and deaths in 2,026 U.S. counties from January to October 2020 and social determinants of health, which can raise the risk for infection and death.
They also looked at factors known or thought to impact COVID-19 outcomes, including the counties' population density, days since the first COVID-19 death and percent of residents who are over age 65, are smokers or who have chronic diseases such as obesity, ...
2021-01-30
CHICAGO (January 30, 2021) -- Select patients born with heart defects and who undergo congenital heart surgery recover with few complications and reduced opioid use when a comprehensive, evidence-based enhanced recovery after surgery (ERAS) program is used, according to research presented at the 57th Annual Meeting of The Society of Thoracic Surgeons.
"We have embarked on a new paradigm for patient care with the goal of improving recovery, patient experience, and the value of care that we provide," said Nathalie Roy, MD, from Boston Children's Hospital in Massachusetts. ...
2021-01-30
CHICAGO (January 30, 2021) -- Women are significantly less likely than men to undergo coronary artery bypass grafting (CABG) using guideline-recommended approaches, which may result in worse outcomes after surgery, according to a scientific presentation at the 57th Annual Meeting of The Society of Thoracic Surgeons.
"This study highlights key differences between women and men in surgical techniques used for CABG and reveals opportunities to improve outcomes in women," said Oliver K. Jawitz, MD, from Duke University in Durham, North Carolina.
Using the STS Adult Cardiac Surgery Database--which contains records of nearly all CABG procedures performed in the US--Dr. Jawitz and colleagues from Duke and The Johns Hopkins University ...
2021-01-30
CHICAGO (January 30, 2021) -- The most deadly global health crisis in a century has resulted in a substantial decline in overall heart surgery volume and an unexplained increase in deaths after coronary artery bypass grafting, according to late-breaking research presented at the 57th Annual Meeting of The Society of Thoracic Surgeons.
"This study was a true herculean analysis and tour de force that showed the COVID effect on adult cardiac surgery volume, trends, and outcomes," said Tom C. Nguyen, MD, from the University of California San Francisco. "The pandemic has changed the world as we know it, causing a dramatic drop in adult cardiac surgery volume and worsening patient outcomes."
Dr. Nguyen and colleagues queried the STS Adult ...
2021-01-30
(Singapore--January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST)-- Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
Malignant mesothelioma is an intractable cancer, and no phase III trial has yet shown an improvement in overall survival following the standard first line chemotherapy doublet comprising pemetrexed and cisplatin or carboplatin since it was licensed in 2004.
Professor Dean Fennell, chair of Thoracic Medical Oncology at the University of Leicester in collaboration with Professor Gareth Griffiths and his team at the Southampton Clinical Trials Unit, University of Southampton, ...
2021-01-30
(Singapore--January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST)-- A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
Lung cancer researchers and clinicians have sought methods to improve chemotherapy's modest 5% overall survival rate for patients with NSCLC. Dr. Silvia Novello, professor of medical oncology at the University of Torino at ...
2021-01-30
(Singapore--January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST)-- Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.
Dr. Jay M. Lee, chief, Division of Thoracic Surgery at Ronald Reagan UCLA Medical Center in Los Angeles, today reported on results from a study of 181 patients with stage IB to IIIB non-small cell lung ...
2021-01-30
(Singapore--January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST)-- A study presented today by researchers with the Ministry of Health and Welfare in Taiwan confirmed the effectiveness of low-dose computed tomography (LDCT) screening in a pre-defined, never-smoker, high-risk population. The research was presented today at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.
In Taiwan, lung cancer is the leading cause of cancer mortality, and 53% of those have died of lung cancer were never-smokers. The National Lung Cancer Screening Trial (NLCST) and NELSON Trials demonstrated that the use of low-dose CT is effective for lung cancer screening; however, ...
2021-01-30
(Singapore--4:45 p.m. SPT/3:45 a.m. EST January 30, 2021--Using a host immune classifier (HIC) test for patients with non-small cell lung cancer (NSCLC) may provide better predictors of treatment response and improve outcomes, according to research presented today at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer Singapore.
Immune checkpoint inhibitors have revolutionized cancer care in patients with advanced stage aNSCLC, but better predictors of treatment response are still needed to guide treatment decisions for patients diagnosed with NSCLC, according to Dr. Wallace Akerley, of Huntsman Cancer Institute in Salt Lake City, Utah. HIC (Host Immune Classifier) is a serum proteomic measure of inflammation. ...
2021-01-30
Nagoya University researchers and colleagues have revealed that colorectal cancer tissues contain at least two types of fibroblasts (a type of cells found in connective tissue), namely, cancer-promoting fibroblasts and cancer-restraining fibroblasts, and that the balance between them is largely involved in the progression of colorectal cancer. Their findings, recently published in the journal Gastroenterology, suggest that artificially altering the balance between the two types of cells could curb the spread of colorectal cancer tumors, which may become an effective strategy for preventing cancer progression.
Cancer tissues comprise both cancer cells and non-malignant cells such as fibroblasts. Previous studies have suggested that the proliferation of fibroblasts ...
LAST 30 PRESS RELEASES:
[Press-News.org] Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC
